Interim Results

30 October 2007

LiDCO, the UK-based, AIM-quoted cardiovascular monitoring company, today announces its Interim Results for the six months ended 31 July 2007.

Financial Highlights

• Revenue up 22% at £1.97m (2006: £1.62m)
• Underlying hospital and distributor revenues (sales excluding lease arrangements) up 37% to £1.85m (July 2006: £1.35m)
• Loss before tax cut by 29% to £1.05m (2006: £1.48m)
• Admin and distribution expenses reduced by 5% at £2.57m (2006: £2.71m)
• Operating cash outflow reduced by 31% to £0.97m (2006:  £1.41m)
• Product margins maintained at 75% on monitors, and improved to 87% on disposables (2006: 85%)
• Loss per share reduced by 38% to 0.82p (2006: 1.33p)
• Cash balance £481,000 & Laurus loan facility of $1.9m available (at 31 July 2007)

Corporate Highlights

• Exclusive critical care marketing collaboration with Becton Dickinson UK
• Further clinical outcome studies show reductions in mortality, complications and length of stay
• Demonstration of new remote hemodynamic monitoring product - LiDCOlive
• New anesthesia product LiDCOrapid in clinical trials
• LiDCOrapid patent filed in October

Commercial Highlights

• Continued broad adoption of technology with 40% of installed monitors in the USA, 19% in the UK, 25% in Europe and 16% in the Rest of World
• Installed base of monitors up 17% at 1,128 (July 2006: 962)
• Monitors sold or placed: increased from 39 in the same period in 2006 to 93 units
• Sensors and fees per use volumes up 12% to 13,582 units; sensor sales value increased 17% to more than £1m
• Considerable market growth in Europe, increased by 161% compared with the same period in 2006

Commenting on the results Terry O’Brien, Chief Executive, said: “Significant progress has been made in sales of our computer-based hemodynamic monitoring equipment particularly within the intensive care market. Increased sales are being achieved while maintaining margins and without increases in our administration expenses. Looking forward we are excited about the commercial possibilities of both the impending launch of the anesthesia product – the LiDCOrapid and our corporate collaboration with BD.”

The full results are available to view and download in PDF format.

The investor presentation ‘LiDCO’s Interim Results – six months ended 31st July 2007’ will be available on the LiDCO website (www.lidco.com).